Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Change in Accured Expenses (2017 - 2025)

Historic Change in Accured Expenses for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $1.3 million.

  • Aclaris Therapeutics' Change in Accured Expenses rose 21300.17% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 12252.84%. This contributed to the annual value of -$3.9 million for FY2024, which is 13287.47% down from last year.
  • Per Aclaris Therapeutics' latest filing, its Change in Accured Expenses stood at $1.3 million for Q3 2025, which was up 21300.17% from $399000.0 recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Change in Accured Expenses registered a high of $11.6 million during Q4 2024, and its lowest value of -$12.9 million during Q1 2024.
  • Its 5-year average for Change in Accured Expenses is -$12473.7, with a median of $399000.0 in 2025.
  • Per our database at Business Quant, Aclaris Therapeutics' Change in Accured Expenses skyrocketed by 92848.75% in 2023 and then plummeted by 101267.24% in 2024.
  • Quarter analysis of 5 years shows Aclaris Therapeutics' Change in Accured Expenses stood at $2.5 million in 2021, then tumbled by 126.81% to -$681000.0 in 2022, then skyrocketed by 928.49% to $5.6 million in 2023, then surged by 105.1% to $11.6 million in 2024, then tumbled by 88.81% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $399000.0 for Q2 2025, and -$11.0 million during Q1 2025.